S. 993 · 118th Congress
Combating Illicit Xylazine Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 118th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
Cortez MastoSponsor30 cosponsors · 15 D, 15 R
R
Capito
CG
R
Grassley
MH
D
Hassan
JM
D
Manchin
RM
R
Marshall
JR
R
Risch
JS
D
Shaheen
MK
D
Kelly
KG
D
Gillibrand
MR
R
Rounds
JT
R
Thune
CH
R
Hyde-Smith
SB
D
Brown
RS
R
Scott
AK
D
Klobuchar
MR
R
Rubio
DS
D
Stabenow
RW
R
Wicker
JR
D
Rosen
TY
R
Young
KB
R
Britt
BC
D
Casey
JB
R
Boozman
BL
D
Luján
TK
D
Kaine
JD
R
Vance
MW
D
Warner
TT
R
Tillis
RB
D
Blumenthal
MC
D
Cantwell7 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill criminalizes the illicit use of xylazine. (Xylazine, also known as Tranq , is a sedative that is approved for use in animals. The Drug Enforcement Administration (DEA) has reported an increase in the trafficking of fentanyl mixed with xylazine.)
What it does: CRS summary · Introduced in Senate · Mar 28, 2023
Combating Illicit Xylazine Act
This bill criminalizes the illicit use of xylazine. (Xylazine, also known as Tranq, is a sedative that is approved for use in animals. The Drug Enforcement Administration (DEA) has reported an increase in the trafficking of fentanyl mixed with xylazine.)
Specifically, the bill establishes criminal penalties for manufacturing, distributing, or dispensing, or possessing with intent to manufacture, distribute, or dispense, xylazine for illicit use (i.e., for use in humans) in accordance with the penalties for schedule III substances (up to 10 years imprisonment or, if death or serious bodily injury occurs, up to 15 years imprisonment, as well as criminal fines).
In addition, the DEA must coordinate with the Food and Drug Administration to report on the prevalence of the illicit use of xylazine, including associated supply chains. The bill also declares the illicit use of xylazine as an emerging drug threat.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Combating Illicit Xylazine Act
Latest action (Jan 11, 2024): Committee on Banking, Housing, and Urban Affairs. Hearings held.
Policy area: Crime and Law Enforcement · Origin: Senate · Introduced: Mar 28, 2023
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.